Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction

• Published in: Indian journal of pharmacology 2013-07, Vol.45 (4), p.330-333
• Main Authors: Kulkarni, Shaunak P, Shah, Sanjana R, Kadam, Prashant P, Sridharan, Kannan, Hase, Nivrutti K, Shetty, Partha P, Thatte, Urmila M, Gogtay, Nithya J
• Format: Article
• Language: English
• Subjects: Adult; Antimalarials - administration & dosage; Antimalarials - blood; Antimalarials - pharmacokinetics; Care and treatment; Chronic kidney failure; Clinical trials; Dosage and administration; Drug therapy; Female; Humans; Kidney diseases; Male; Middle Aged; Patient outcomes; Pharmacokinetics; Pharmacology; Primaquine; Primaquine - administration & dosage; Primaquine - blood; Primaquine - pharmacokinetics; Renal Insufficiency, Chronic - metabolism; Side effects; Young Adult
• ISSN: 0253-7613; 1998-3751; 1998-3751
• DOI: 10.4103/0253-7613.114997

The pharmacokinetics of primaquine has not been studied in special populations. Being a basic compound, preferential binding to alpha-1 acid glycoprotein and substrate for P-glycoprotein, may predispose the drug for an altered pharmacokinetics in states of renal dysfunction. This study attempts to evaluate the pharmacokinetics of a single oral dose (15 mg) of primaquine in severely impaired renal function and end stage renal dysfunction patients compared to healthy participants. Twelve patients each with chronic kidney disease classified as either Stage IV or V (not on dialysis) were recruited. Data from 12 healthy participants was used as concurrent controls. Serial blood collections were performed following a single dose 15 mg Primaquine orally. Primaquine concentrations were measured in the plasma using a validated HPLC method. The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively. No statistically significant difference was observed in any of the pharmacokinetic parameters between healthy, stage IV and V CKD participants. Pharmacokinetics of single oral dose primaquine (15 mg) does not appear to be altered in patients with severely impaired renal function and end stage renal dysfunction. A change in dose or frequency of the drug administration perhaps may not be required in this population.